FDA Decision on ONS-5010 Expected This Month Following Dispute Resolution
OTLK sits 45% above its 52-week low of $0.161.
Summary
Outlook Therapeutics announced that a formal FDA decision regarding the Complete Response Letter (CRL) for ONS-5010 is expected in May 2026, following a completed dispute resolution meeting in April. While the reported Q2 FY2026 net loss of $4.5 million and adjusted net loss of $14.1 million were previously disclosed in a news release and 10-Q filing on May 15, the specific timeline for the FDA decision is new and highly material. This update is critical for the company, which recently filed a 10-Q with a going concern warning and launched a $100 million At-The-Market offering. The upcoming FDA decision represents a significant near-term catalyst that could substantially impact the company's future and stock valuation.
At the time of this announcement, OTLK was trading at $0.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.5M. The 52-week trading range was $0.16 to $3.39. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Wiseek News.